Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2017 Jan 21;23(3):533-539.
doi: 10.3748/wjg.v23.i3.533.

Efficacy and safety of stellate ganglion block in chronic ulcerative colitis

Hong-Ying Zhao  1 , Guo-Tao Yang  1 , Ning-Ning Sun  1 , Yu Kong  1 , Yun-Feng Liu  1
Affiliations
Observational Study

Efficacy and safety of stellate ganglion block in chronic ulcerative colitis

Hong-Ying Zhao et al. World J Gastroenterol. .

Abstract

Aim: To investigate the efficacy and safety of stellate ganglion block for the treatment of patients with chronic ulcerative colitis.

Methods: A total of 120 randomly selected patients with chronic ulcerative colitis treated in Cangzhou Central Hospital from January 2014 to January 2016 were included in this study. These patients were divided into two groups: control group (n = 30), patients received oral sulfasalazine treatment; experimental group (n = 90), patients received stellate ganglion block treatment. Clinical symptoms and disease activity in these two groups were compared before and after treatment using endoscopy. Blood was collected from patients on day 0, 10, 20 and 30 after treatment. Enzyme-linked immunosorbent assay was performed to determine interleukin-8 (IL-8) level. The changes in IL-8 level post-treatment in the two groups were compared using repeated measures analysis of variance.

Results: After treatment, clinical symptoms and disease activity were shown to be alleviated by endoscopy in both the control and experimental groups. However, patients in the control group did not have obvious abdominal pain relief. In addition, the degree of pain relief in the experimental group was statistically better than that in the control group (P < 0.05). Ten days after treatment, IL-8 level was found to be significantly lower in the experimental group than in the control group, and the difference was statistically significant (P < 0.05). In addition, adverse events were significantly higher in the control group than in the experimental group, and the difference was statistically significant (χ2 = 33.215, P = 0.000).

Conclusion: The application of stellate ganglion block effectively improves treatment efficacy in chronic ulcerative colitis, relieves clinical symptoms in patients, and reduces the level of inflammatory factors. Furthermore, this approach also had a positive impact on the disease to a certain extent.

Keywords: Chronic ulcerative colitis; Stellate ganglion block.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: No potential conflicts of interest relevant to this article were reported.

Figures

Figure 1
Figure 1
Interactive contour map of time points and group factors. IL-8: Interleukin-8.
Figure 2
Figure 2
Colonoscopy scores of patients in the two groups. aP < 0.05 vs the control group before treatment; aP < 0.05 vs the control group after treatment.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dugani A, Dakhil B, Treesh S. Protective effect of the methanolic extract of malva parviflora l. leaves on acetic acid-induced ulcerative colitis in rats. Saudi J Gastroenterol. 2016;22:226–233. - PMC - PubMed
    1. Postovalova EA, Khochansky DN, Zolotova NA, Gao Y, Makarova OV, Dobrynina MT. Morphological Changes in Mesenteric Lymph Nodes and Lymphocyte Subpopulation Composition in Experimental Ulcerative Colitis. Bull Exp Biol Med. 2016;160:835–839. - PubMed
    1. Wanderås MH, Moum BA, Høivik ML, Hovde Ø. Predictive factors for a severe clinical course in ulcerative colitis: Results from population-based studies. World J Gastrointest Pharmacol Ther. 2016;7:235–241. - PMC - PubMed
    1. Nidhi M, Kaur V, Hallan SS, Sharma S, Mishra N. Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: A brief review. Saudi Pharm J. 2016;24:458–472. - PMC - PubMed
    1. Zizi O, Benfor B, Jiber H, Bouarhroum A. Embolic lower limb ischemia as a rare complication of ulcerative colitis: A case report and literature review. J Mal Vasc. 2016;41:279–285. - PubMed

Publication types

MeSH terms